ASM Biothreats offers professionals in biodefense, biosecurity and biological threats the opportunity to exchange knowledge and ideas that will shape the future of this emerging field. ASM Biothreats offers a unique program that explores the latest developments and emerging technologies in the industry.
Collaborate with more than 1,500 scientists, program managers and leaders from across the globe who are committed to making the world safer by confronting chemical and biological defense challenges.
The Biomedical Advanced Research and Development Authority (BARDA) annual Industry Day 2019 conference on US government medical countermeasures is planned October 2019.
This statement discusses US Government Accountability (GAO) reports issued from December 2009 through March 2019 on various biological threats and biodefense efforts. To conduct prior work, GAO reviewed biodefense reports, relevant presidential directives, laws, regulations, policies, strategic plans; surveyed states; and interviewed federal, state, and industry officials, among others.
The Fifth Annual Biodefense World Summit brings together leaders from government, academia, and industry for discussions on pathogen detection, point-of-care, biosurveillance, sample prep technologies, and bio-recovery.
Collaborating with industry to highlight a one-team concept is a top priority for the Department of Defense. The Pentagon is committed to accelerating and adapting the traditional acquisition process to improve readiness and modernize the Joint Force. As the DOD modernizes the force, we are modernizing this conference. Anticipate in-depth discussions on the evolving threat, needed future capabilities, acquisition reform, and the future of Warfighter training.
This workshop introduces participants to the challenges facing the world at the intersection of national security, public health, and the life sciences.
The National Biodefense Strategy considers that biological threats are among the most serious potential threats facing the US and the international community and recognizes that it is a vital interest of the United States to manage the risks arising from such threats.
This review examines evidence from the history of variolation, data on mucosal infection collected in the last decades of smallpox transmission, aerosol measurements, animal models, reports of smallpox lung among healthcare workers, and the epidemiology of smallpox regarding the potential importance of fine particle aerosol mediated transmission.
The US National Biodefense Strategy, released last year, highlights the need to reduce the emergence and spread of superbugs both domestically and internationally, and accelerate the development of new drugs, diagnostic tests, and vaccines.